Ukrain in the treatment of urethral recurrent carcinoma (case report).

In a patient with low grade differentiated urethral carcinoma (histologically: urothelial carcinoma G2 and G3, pT1 with low grade differentiation) operation was carried out, with recurrence after two months. Instead of reoperation the patient was given Ukrain as monotherapy. No carcinoma was detected four months later by histological examination or during examinations three years later.

Ukrain monotherapy in malignant melanoma (case report).

A patient with a metastasizing malignant melanoma (stage III) was treated with Ukrain monotherapy. Before and during the first Ukrain course of treatment the patient excreted melanin in the urine. After the third course melanin was no more detectable and the patient has been without any symptoms of disease for the last 12 years.

Influence of Ukrain on immunological blood parameters in vitro and in vivo.

Immunological changes are often seen in subjects suffering from oncological disease. Decreased NK activity, alterations of the T4/T8 quotient, decreased phagocytic activity, low reactivity and decreased recognition of the "foreign" are common features seen in these patients. Cytostatic therapy (chemotherapy and radiation therapy) very often enhance these negative properties, thus limiting therapeutic possibilities by highly toxic sequels.

Influence of Ukrain on human xenografts in vitro.

Tumour cells were taken from human tumour xenografts (HTX) and serially transplanted into nude mice. These cells were used in a colony-forming assay in vitro. Tumour cells were incubated continuously for at least one week with several concentrations of the drug Ukrain.

Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells.

3H labelled thymidine, uridine and leucine were used to evaluate the synthesis of DNA, RNA and proteins in malignant cells and normal cells incubated with Ukrain in different concentrations. Compared with the controls, the inhibiting effects of Ukrain are demonstrated in guinea pig hepatocytes, CIL hepatocytes, human tonsil cells, two murine lymphomas, murine myeloma, Yoshida cells, two HeLa strains, EsB- and EB- (murine) lymphomas. YAC-1, P815 and human WiDr cells.